<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007236</url>
  </required_header>
  <id_info>
    <org_study_id>RP7214-2101</org_study_id>
    <nct_id>NCT05007236</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild SARS-CoV-2 Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incozen Therapeutics Pvt Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with&#xD;
      symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age &gt; 60&#xD;
      years, hypertension, diabetes mellitus, chronic lung disease, chronic kidney disease, liver&#xD;
      disease, cerebrovascular disease, obesity, cancer) for developing severe Covid-19 illness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients requiring Covid-19 related hospitalization by Day 15.</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SARS-CoV-2 viral load at Days 3, 7 and 15 by quantitative RT-PCR test</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom resolution in patients receiving RP7214 as compared to placebo</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients demonstrating symptom resolution</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom improvement in patients receiving RP7214 as compared to placebo</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients demonstrating symptom improvement</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) as assessed by laboratory tests, vital signs and physical examination.</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the disease-specific inflammatory markers (Ferritin, C-reactive protein (CRP), D-dimer, neutrophil to lymphocyte/CD8+ ratio, LDH, IL-6) as compared to baseline.</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>RP7214 + Standard of care (SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Standard of care (SOC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP7214 + Standard of care (SOC)</intervention_name>
    <description>RP7214 tablets will be administered orally twice a day for 14 days</description>
    <arm_group_label>RP7214 + Standard of care (SOC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Standard of care (SOC)</intervention_name>
    <description>Placebo will be administered orally twice a for 14 days</description>
    <arm_group_label>Placebo + Standard of care (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent.&#xD;
&#xD;
          2. Males and females of ≥ 18 years of age&#xD;
&#xD;
          3. Patient with mild COVID-19 infection having ≥ 1 symptoms.&#xD;
&#xD;
          4. Laboratory confirmed Covid-19 infection by Reverse Transcription Polymerase Chain&#xD;
             Reaction (RT-PCR) in nasopharyngeal sample (within 72 hours prior to randomization).&#xD;
&#xD;
          5. Patient should have at least one pre-existing high-risk feature for developing severe&#xD;
             Covid-19 illness.&#xD;
&#xD;
          6. Ability to swallow and retain oral medication.&#xD;
&#xD;
          7. Male patient who is surgically sterile, or who is willing to agree to use a&#xD;
             contraceptive measure.&#xD;
&#xD;
          8. Women of childbearing potential should be willing to use a medically acceptable method&#xD;
             of contraception.&#xD;
&#xD;
          9. Willing to receive telephone calls or have videoconferences with study team personnel.&#xD;
&#xD;
         10. Willing and able to understand the nature of this study, comply with the study&#xD;
             procedures and follow-up procedures as per the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with asymptomatic Covid-19 infection.&#xD;
&#xD;
          2. Patient who has experienced the onset of any of Covid-19 symptoms &gt; 5 days at the time&#xD;
             of randomization.&#xD;
&#xD;
          3. Moderate to Severe COVID-19 infection&#xD;
&#xD;
          4. Patient with Covid-19 re-infection&#xD;
&#xD;
          5. Subjects who are severely immunocompromised&#xD;
&#xD;
          6. Subjects with autoimmune diseases&#xD;
&#xD;
          7. Patients with any bleeding disorder e.g., hemophilia and von Willebrand disease.&#xD;
&#xD;
          8. Current use of other DHODH inhibitors including teriflunomide or leflunomide.&#xD;
&#xD;
          9. Patients who are on or immediately require Covid-19 directed treatment such as&#xD;
             antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous&#xD;
             steroids, or monoclonal antibodies at the time of screening.&#xD;
&#xD;
         10. Patients who have had received one or two doses of vaccine for Covid-19.&#xD;
&#xD;
         11. Patients participating in another clinical study or use of any investigational product&#xD;
             within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of&#xD;
             dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prajak Barde, MD</last_name>
    <phone>+41325800175</phone>
    <email>pjb@rhizen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Panimalar medical college hospital and research institute</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satish Kumar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Eastern medical school and hospital</name>
      <address>
        <city>Srikakulam</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Sudheer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

